Rexahn Pharmaceuticals Inc. (RNN)

0.61
AMEX : Health Technology
Prev Close 0.61
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.55 / 2.50
Avg Volume 307.10K
Exchange AMEX
Shares Outstanding 37.52M
Market Cap 37.90M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction In A Phase IIa Clinical Study

Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction In A Phase IIa Clinical Study

Phase IIa Clinical Data Presented at the ASCO 2016 Genitourinary Cancers Symposium

Rexahn Pharmaceuticals Announces New Data For Supinoxin™ Showing Potent Tumor Growth Inhibition

Rexahn Pharmaceuticals Announces New Data For Supinoxin™ Showing Potent Tumor Growth Inhibition

New Data Demonstrate Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Triple Negative Breast Cancer

Rexahn Pharmaceuticals Reports Interim Clinical Data For Archexin® At The 14th International Kidney Cancer Symposium

Rexahn Pharmaceuticals Reports Interim Clinical Data For Archexin® At The 14th International Kidney Cancer Symposium

Interim Data Show Archexin is Well Tolerated at the Doses Tested to Date With Early Evidence of Anti-Tumor Activity Observed in a Phase IIa Clinical Study in Metastatic Renal Cell Carcinoma

4 Stocks Under $10 Making Big Up Moves on Big Volume

4 Stocks Under $10 Making Big Up Moves on Big Volume

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Corporate Update

Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Corporate Update

Interim Data Suggest Potential Clinical Activity of Supinoxin™ and RX-3117 Anti-Cancer Therapies

Rexahn Pharmaceuticals Presents Preliminary Clinical Data For Supinoxin(TM) And RX-3117 Oncology Programs At The European Cancer Congress 2015

Rexahn Pharmaceuticals Presents Preliminary Clinical Data For Supinoxin(TM) And RX-3117 Oncology Programs At The European Cancer Congress 2015

Supinoxin(TM) and RX-3117 Are Safe and Well Tolerated in Cancer Patients With Advanced and Metastatic Solid Tumors and Demonstrate Preliminary Evidence of Clinical Activity

Rexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Corporate Update

Rexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Corporate Update

Presentations at Recent Scientific Conferences Showcase Novel Anti-Tumor Properties of Rexahn Compounds

National Cancer Institute Accepts Rexahn's RX-21101 For Its Nanotechnology Characterization Laboratory's Preclinical Characterization Program

National Cancer Institute Accepts Rexahn's RX-21101 For Its Nanotechnology Characterization Laboratory's Preclinical Characterization Program

Program Will Provide Foundation for Filing an IND Application for Phase I Trial

5 Stocks Under $10 Ready to Spike Higher

5 Stocks Under $10 Ready to Spike Higher

These under-$10 stocks look poised to breakout out and trade higher from current levels.

Rexahn Pharmaceuticals Reports First Quarter 2015 Financial Results And Pipeline Update

Rexahn Pharmaceuticals Reports First Quarter 2015 Financial Results And Pipeline Update

New Data on RX-3117 and Supinoxin(TM) Substantially Increase Excitement Around These Programs in Scientific and Clinical Oncology Communities

New Data Show Rexahn's Supinoxin(TM) Decreases The Migration Of Human Triple Negative Breast Cancer Cells In A Metastatic Cancer Model

New Data Show Rexahn's Supinoxin(TM) Decreases The Migration Of Human Triple Negative Breast Cancer Cells In A Metastatic Cancer Model

Data Presented at 2015 American Association for Cancer Research (AACR) Annual Meeting

Rexahn Identifies RX-3117 Biomarker & Presents Data At The 2015 American Association For Cancer Research Annual Meeting

Rexahn Identifies RX-3117 Biomarker & Presents Data At The 2015 American Association For Cancer Research Annual Meeting

RX-3117 Antitumor Activity Correlates With UCK2 Enzymatic Activity